Related Experiment Video

Updated: Jun 18, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Device therapy and cardiac transplantation for end-stage heart failure

Barry A Boilson, Eugenia Raichlin, Soon J Park

    Current Problems in Cardiology
    |December 8, 2009
    PubMed

    Insights

    End-stage heart failure treatment is limited by donor organ availability. Mechanical circulatory support, like left ventricular assist devices (LVADs), offers improved outcomes and future potential for earlier intervention.

    Area of Science:

    • Cardiology
    • Biomedical Engineering
    • Regenerative Medicine

    Background:

    • Heart failure prevalence is rising, with poor prognosis in end-stage cases.
    • Cardiac transplantation is the gold standard but faces donor organ scarcity.
    • Mechanical circulatory support devices have improved outcomes for transplant candidates.

    Purpose of the Study:

    • To review current therapeutic options for end-stage heart failure.
    • To explore potential future treatments for advanced heart failure.
    • To discuss the evolving role of mechanical support and novel therapies.

    Main Methods:

    • Review of current literature on heart failure treatments.
    • Analysis of advancements in mechanical circulatory support (LVADs, TAH).
    • Exploration of emerging strategies like cell therapy and xenotransplantation.

    Main Results:

    • Left ventricular assist devices (LVADs) reduce mortality and morbidity.
    • LVADs are approved for destination therapy and show potential for earlier stages.
    • Cell therapy and xenotransplantation are under investigation as alternative strategies.

    Conclusions:

    • Mechanical support devices are crucial for managing end-stage heart failure.
    • Future LVAD advancements may enable use in earlier stages of heart failure.
    • Novel therapies like cell therapy and xenotransplantation hold promise for future treatment paradigms.

    More Related Videos

    Implantation of the Syncardia Total Artificial Heart16:11

    Implantation of the Syncardia Total Artificial Heart

    Published on: July 18, 2014

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

    Published on: September 22, 2014

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...